FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical composition for HIV-1 replication inhibition containing a compound of Formula
,
wherein n is equal to 1 or 2; Ar means phenyl substituted by one substitute specified in a group consisting of OH and NO2, or by two substitutes OR, or thienyl; R1 is specified in a group consisting of R6, C(O)N(R6)2, and C1-C6 alkyl substituted by OR; R2 means H or C1-C6 alkyl; R6 is independently in each specific case specified in H and C1-C6 alkyl; each R independently represents C1-C8 alkyl; or its pharmaceutically acceptable salt, or a compound 1G3, or its pharmaceutically acceptable salt. Also, the invention refers to a method of treating an individual either HIV-1 infected or suffering a high risk of HIV-1 infection involving administration of the above composition, to a method for HIV-1 virus replication inhibition.
EFFECT: what is prepared is the new pharmaceutical composition possessing effective biological properties 1G3.
11 cl, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROBICYCLIC HEPATITIS C VIRUS (HCV) INHIBITORS | 2006 |
|
RU2405783C2 |
| SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | 2013 |
|
RU2681209C2 |
| QUINOLONE ANALOGUES AND RELATED METHODS | 2008 |
|
RU2549895C2 |
| COMBINATION OF HDA INHIBITOR AND ANTIMETABOLITE | 2007 |
|
RU2469717C2 |
| COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2763544C2 |
| METHOD OF TREATING DISORDERS ASSOCIATED WITH ALKYLATING AGENT EXPOSURE | 2009 |
|
RU2506083C2 |
| METHODS AND PRODUCTS FOR HEALING TISSUE WOUNDS | 2012 |
|
RU2652308C2 |
| HYDROXAMATE DERIVATIVES SUITABLE AS DEACETYLASE INHIBITORS | 2001 |
|
RU2302408C2 |
| UROKINASE INHIBITORS ADMINISTRATION FOR TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | 2006 |
|
RU2410087C2 |
| NOVEL DERIVATIVES OF IMIDAZOLIDINE, THEIR PREPARING AND USING AS VLA-4 ANTAGONIST | 2002 |
|
RU2318815C2 |
